Frank de Vries

Frank de Vries

Auto-generated profile, based on publicly available information

Frank de Vries

Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, the Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Bone
Verified
Journal Article
Closed access
ECElizabeth M. Curtis
Elizabeth M. Curtis
RVRobert van der Velde
Robert van der Velde
RMRebecca J. Moon
Rebecca J. Moon
PBPeter Van Den Berg
Peter Van Den Berg
PGPiet Geusens
Piet Geusens
NHNicholas C. Harvey
Nicholas C. Harvey

2 January 2007 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
FVFrank De Vries
Frank De Vries
MBMadelon Bracke
Madelon Bracke
HLHubert G. M. Leufkens
Hubert G. M. Leufkens
JLJan‐Willem J. Lammers
Jan‐Willem J. Lammers
CCCyrus Cooper
Cyrus Cooper
VSVictoria van Staa
Victoria van Staa
Objective: To evaluate the risk of fracture in patients receiving intermittent therapy with high‐dose oral glucocorticoids (GCs).Methods: The study group comprised 191,752 patients from the UK General Practice Database who were 40 years of age and older and received therapy with GCs. The followup time period was divided into the categories of “current” and “no exposure.” The daily dose and cumulative dose for each time period were determined. Relative risks were estimated using Cox proportional hazards models, adjusted for age, sex, body mass index, smoking, disease history, and drug history. Fractures of the radius/ulna, humerus, rib, femur/hip, pelvis, or vertebrae were included in the evaluation.Results: Patients who intermittently received high‐dose GCs (daily dose ≥15 mg) and had no or little previous exposure to GCs (cumulative exposure ≤1 gm) had a small increased risk of osteoporotic (but not hip/femur) fracture; this risk increased substantially with increasing cumulative exposure. Among patients who received a daily dose ≥30 mg and whose cumulative exposure was >5 gm, the relative risk (RR) of osteoporotic fracture was 3.63 (95% confidence interval [95% CI] 2.54–5.20), the RR of fracture of the hip/femur was 3.13 (95% CI 1.49–6.59), and the RR of vertebral fracture was 14.42 (95% CI 8.29–25.08).Conclusion: Intermittent use of high‐dose oral GCs (daily dose ≥15 mg and cumulative exposure ≤1 gm) may result in a small increased risk of osteoporotic fracture. Conversely, patients who receive several courses of high‐dose GCs (daily dose ≥15 mg and cumulative exposure >1 gm) have a substantially increased risk of fracture.

11 April 2001 in JAMA
Verified
Journal Article
Open access
PDF file
VSVictoria van Staa
Victoria van Staa
SWSebastiaan Wegman
Sebastiaan Wegman
FVFrank de Vries
Frank de Vries
BLBert Leufkens
Bert Leufkens
CCCyrus Cooper
Cyrus Cooper
Synthesis of cholesterol is reduced by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the liver, which catalyzes conversion of HMG-CoA to mevalonic acid. Statins have been shown to be reversible, competitive inhibitors of this enzyme and, thus, are currently used for clinical treatment of hypercholesterolemia.1,2 Mevalonic acid has been found to be a precursor not only of cholesterol but also of proteins such as geranylgeranyl pyrophosphate, which is important in the control of osteoclast-mediated bone resorption. Nitrogen-containing bisphosphonates, such as alendronate and risedronate, may exert their antiresorptive action by suppressing the generation of geranylgeranyl pyrophosphate in the mevalonate pathway.3 Furthermore, recent animal and in vitro research has led to a hypothesis that statins may reduce risk of fractures.4 Some epidemiological studies have reported reductions in fracture risk,5-8 but the preliminary results of a large follow-up study have not confirmed these observations.9 Given the widespread use of statins, the possible effects on fracture is an important clinical issue. We performed a population-based case-control study in which a history of statin use in fracture cases was compared with that among age- and sex-matched control patients.

9 March 2016 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
BVB. P. M. Verhaegh
B. P. M. Verhaegh
FVF. de Vries
F. de Vries
AMA. A. M. Masclee
A. A. M. Masclee
AKA. Keshavarzian
A. Keshavarzian
ABA. de Boer
A. de Boer
DJD. M. A. E. Jonkers
D. M. A. E. Jonkers

15 September 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
SWShirley V. Wang
Shirley V. Wang
SSSebastian Schneeweiss
Sebastian Schneeweiss
MBMarc L. Berger
Marc L. Berger
JBJeffrey Brown
Jeffrey Brown
FVFrank de Vries
Frank de Vries
OMon behalf of the joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making
on behalf of the joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making
Purpose: Defining a study population and creating an analytic dataset from longitudinal healthcare databases involves many decisions. Our objective was to catalogue scientific decisions underpinning study execution that should be reported to facilitate replication and enable assessment of validity of studies conducted in large healthcare databases.Methods: We reviewed key investigator decisions required to operate a sample of macros and software tools designed to create and analyze analytic cohorts from longitudinal streams of healthcare data. A panel of academic, regulatory, and industry experts in healthcare database analytics discussed and added to this list.Conclusion: Evidence generated from large healthcare encounter and reimbursement databases is increasingly being sought by decision‐makers. Varied terminology is used around the world for the same concepts. Agreeing on terminology and which parameters from a large catalogue are the most essential to report for replicable research would improve transparency and facilitate assessment of validity. At a minimum, reporting for a database study should provide clarity regarding operational definitions for key temporal anchors and their relation to each other when creating the analytic dataset, accompanied by an attrition table and a design diagram.A substantial improvement in reproducibility, rigor and confidence in real world evidence generated from healthcare databases could be achieved with greater transparency about operational study parameters used to create analytic datasets from longitudinal healthcare databases.

31 December 2014 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
PPPaul J.H.L. Peeters
Paul J.H.L. Peeters
MBMarloes T. Bazelier
Marloes T. Bazelier
HLHubert G.M. Leufkens
Hubert G.M. Leufkens
FVFrank de Vries
Frank de Vries
MBMarie L De Bruin
Marie L De Bruin
OBJECTIVE To assess the risk of colorectal cancer associated with type 2 diabetes, as compared with a nondiabetic reference population, and to study additional associations between treatment stage and duration of obesity and colorectal cancer risk. RESEARCH DESIGN AND METHODS We conducted an observational population-based cohort study within the Clinical Practice Research Datalink (1987–2012). All patients (≥18 years) with at least one prescription for an antidiabetic drug (n = 300,039) were matched (1:1) by birth year, sex, and practice to a comparison cohort without diabetes. Cox proportional-hazards models were used to derive adjusted hazard ratios (HRs) for colorectal cancer associated with type 2 diabetes. Within the diabetic cohort, associations of colorectal cancer with treatment stages and duration of obesity (BMI ≥30) were studied. RESULTS After a median follow-up of 4.5 years, 2,759 cases of colorectal cancer were observed among the diabetic study population. Type 2 diabetes was associated with a 1.3-fold increased risk of colorectal cancer (HR 1.26 [95% CI 1.18–1.33]). Among diabetic patients, no association was found with treatment stages. A trend of increased colorectal cancer risk was observed with longer duration of obesity. Risk of colorectal cancer was significantly increased for patients with recorded duration of obesity of 4–8 years (HR 1.19 [1.06–1.34]) and >8 years (1.28 [1.11–1.49]). CONCLUSIONS Type 2 diabetes is associated with a moderately increased risk of colorectal cancer. Among diabetic patients, an increased risk was observed for patients who suffered from obesity for a total duration of 4 years or more.